Postoperative Treatment of Carvedilol Following Low Dose Landiolol has Preventive Effect for Atrial Fibrillation after Coronary Artery Bypass Grafting

Abstract

Background: Postoperative atrial fibrillation (AF) is the most common complication after coronary artery bypass grafting (CABG). We have reported that the intra- and perioperative administration of landiolol has a preventive effect on postoperative AF in the early postoperative period after CABG surgery. The purpose of this study was to investigate the prophylactic effect of postoperative treatment with carvedilol following landiolol against postoperative AF. Methods: We reviewed all patients who underwent CABG from December 2005 and February 2009. Fifty-three patients underwent scheduled isolated CABG and were divided two groups; carvedilol group (n = 31), and control group (n = 22). Incidences of postoperative AF were noted. Results: There was no statistical difference between the two groups with regard to the occurrence of AF after CABG. The maximum ventricular rate of AF was significantly lower in the carvedilol group than in the control group. All patients with AF in the control group needed treatment for tachycardia, but this was not necessary in the carvedilol group. Conclusions: Postoperative treatment with carvedilol following landiolol has the effect of preventing tachycardia during AF after coronary artery bypass grafting.

coronary bypass surgery - atrial fibrillation - β‐adrenoceptor antagonist

References

• 1 Almassi G H, Schowalter T, Nicolosi A C, Aggarwal A, Moritz T E, Henderson W G et al. Atrial fibrillation after cardiac surgery: a major morbid event?.  Ann Surg. 1997;  226 501-511 discussion 511-513
• 2 Hogue Jr C W, Hyder M L. Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment.  Ann Thorac Surg. 2000;  69 300-306
• 3 Maisel W H, Rawn J D, Stevenson W G. Atrial fibrillation after cardiac surgery.  Ann Intern Med. 2001;  135 1061-1073
• 4 Zaman A G, Archbold R A, Helft G, Paul E A, Curzen N P, Mills P G. Atrial fibrillation after coronary artery bypass surgery: a model for preoperative risk stratification.  Circulation. 2000;  101 1403-1408
• 5 Creswell L L, Schuessler R B, Rosenbloom M, Cox J L. Hazards of postoperative atrial arrhythmias.  Ann Thorac Surg. 1993;  56 539-549
• 6 Crystal E, Connolly S J, Sleik K, Ginger T J, Yusuf S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.  Circulation. 2002;  106 75-80
• 7 Merrick A F, Odom N J, Keenan D J, Grotte G J. Comparison of propafenone to atenolol for the prophylaxis of postcardiotomy supraventricular tachyarrhythmias: a prospective trial.  Eur J Cardiothorac Surg. 1995;  9 146-149
• 8 Fujiwara H, Sakurai M, Namai A. Administration of low dose landiolol, an ultrashort-acting β-blocker, had preventive effect for postoperative atrial fibrillation after CABG surgery.  Gen Thorac Cardiovasc Surg. 2009;  57 132-137
• 9 Gilbert E M, Abraham W T, Olsen S, Hattler B, White M, Mealy P et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart.  Circulation. 1996;  94 2817-2825
• 10 Arumanayagam M, Chan S, Tong S, Sanderson J E. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial.  J Cardiovasc Pharmacol. 2001;  37 48-54
• 11 Azevedo E R, Kubo T, Mak S, Al-Hesayen A, Schofield A, Allan R et al. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity.  Circulation. 2001;  104 2194-2199
• 12 Poole-Wilson P A, Cleland J G, Di Lenarda A, Hanrath P, Komajda M, Metra M et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET.  Eur J Heart Fail. 2002;  4 321-329
• 13 Merritt J C, Niebauer M, Tarakji K, Hammer D, Mills R M. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation.  Am J Cardiol. 2003;  92 735-736
• 14 Tsuboi J, Kawazoe K, Izumoto H, Okabayashi H. Postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting.  Circ J. 2008;  72 588-591
• 15 Grogan M, Smith H C, Gersh B J, Wood D L. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy.  Am J Cardiol. 1992;  69 1570-1573
• 16 Aranki S F, Shaw D P, Adams D H, Rizzo R J, Couper G S, VanderVliet M et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources.  Circulation. 1996;  94 390-397
• 17 Hashimoto K, Ilstrup D M, Schaff H V. Influence of clinical and hemodynamic variables on risk of supraventricular tachycardia after coronary artery bypass.  J Thorac Cardiovasc Surg. 1991;  101 56-65
• 18 Caretta Q, Mercanti C A, De Nardo D, Chiarotti F, Scibilia G, Reale A et al. Ventricular conduction defects and atrial fibrillation after coronary artery bypass grafting. Multivariate analysis of preoperative, intraoperative and postoperative variables.  Eur Heart J. 1991;  12 1107-1111
• 19 Fuller J A, Adams G G, Buxton B. Atrial fibrillation after coronary artery bypass grafting. Is it a disorder of the elderly?.  J Thorac Cardiovasc Surg. 1989;  97 821-825
• 20 Eagle K A, Guyton R A, Davidoff R, Ewy G A, Fonger J, Gardner T J et al. ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 guidelines for coronary artery bypass graft surgery).  Circulation. 1999;  100 1464-1480
• 21 Pires L A, Wagshal A B, Lancey R, Huang S K. Arrhythmias and conduction disturbances after coronary artery bypass graft surgery: epidemiology, management, and prognosis.  Am Heart J. 1995;  129 799-808
• 22 Atarashi H, Kuruma A, Yashima M, Saitoh H, Ino T, Endoh Y et al. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias.  Clin Pharmacol Ther. 2000;  68 143-150
• 23 Metra M, Giubbini R, Nodari S, Boldi E, Modena M G, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol.  Circulation. 2000;  102 546-551
• 24 Yue T L, Cheng H Y, Lysko P G, McKenna P J, Feuerstein R, Gu J L et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger.  J Pharmacol Exp Ther. 1992;  263 92-98
• 25 Bril A, Slivjak M, DiMartino M J, Feuerstein G Z, Linee P, Poyser R H et al. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol.  Cardiovasc Res. 1992;  26 518-525